0001628280-23-042828.txt : 20231228 0001628280-23-042828.hdr.sgml : 20231228 20231228174449 ACCESSION NUMBER: 0001628280-23-042828 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231226 FILED AS OF DATE: 20231228 DATE AS OF CHANGE: 20231228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Renz Justin A CENTRAL INDEX KEY: 0001466562 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36485 FILM NUMBER: 231523604 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 85 WELLS AVENUE, SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ARDELYX, INC. CENTRAL INDEX KEY: 0001437402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 BUSINESS PHONE: 510-745-7047 MAIL ADDRESS: STREET 1: 34175 ARDENWOOD BLVD. CITY: FREMONT STATE: CA ZIP: 94555 FORMER COMPANY: FORMER CONFORMED NAME: NTERYX INC DATE OF NAME CHANGE: 20080611 4 1 wk-form4_1703803478.xml FORM 4 X0508 4 2023-12-26 0 0001437402 ARDELYX, INC. ARDX 0001466562 Renz Justin A C/O ARDELYX, INC. 400 FIFTH AVENUE, SUITE 210 WALTHAM MA 02451 0 1 0 0 Chief Financial Officer 1 Common Stock 2023-12-26 4 M 0 75000 0.99 A 407426 D Common Stock 2023-12-26 4 S 0 225000 6.3561 D 182426 D Stock Option (Right to Buy) 0.99 2023-12-26 4 M 0 75000 0 D 2032-01-06 Common Stock 75000 121000 D Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2023. This transaction was executed in multiple trades in prices ranging from $6.28 to $6.45, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. /s/ Elizabeth Grammer, Attorney-in-Fact for Justin Renz 2023-12-28